Santen Pharmaceutical Co (TSE:4536) Cyclically Adjusted Revenue per Share: 円751.49 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4536 Santen Pharmaceutical Co Ltd TSE:4536
88 GF Score
Price 円1,916.00
GF Value 円1,722.07
Valuation Modestly Overvalued
View Full Analysis

What is Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Santen Pharmaceutical Co TSE:4536 +0.87% 88 Cyclically Adjusted Revenue per Share is 円751.49 as of Jun. 2026. GuruFocus rates TSE:4536 with a GF Score™ of 88/100 and a GF Value™ of 円1,722.07 (Modestly Overvalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Santen Pharmaceutical Co's adjusted revenue per share for the three months ended in Jun. 2026 was 円213.753. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円751.49 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Santen Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 6.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Santen Pharmaceutical Co was 10.70% per year. The lowest was 8.40% per year. And the median was 9.30% per year.

As of today (2026-08-19), Santen Pharmaceutical Co's current stock price is 円1916.00. Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was 円751.49. Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.55.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Santen Pharmaceutical Co was 5.62. The lowest was 1.77. And the median was 2.86.


Santen Pharmaceutical Co  (TSE:4536) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1916.00/751.49
=2.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Santen Pharmaceutical Co was 5.62. The lowest was 1.77. And the median was 2.86.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 511.91 570.54 629.83 694.23 738.15

Santen Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 705.07 714.00 728.22 738.15 751.49

TSE:4536 vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4536
88GF Score
Santen Pharmaceutical Co Ltd TSE:4536
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Santen Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=213.753/113.6000*113.6000
=213.753

Current CPI (Jun. 2026) = 113.6000.

Santen Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 115.158 98.000 133.489
201612 129.256 98.400 149.222
201703 118.781 98.100 137.549
201706 137.248 98.500 158.288
201709 134.447 98.800 154.587
201712 141.718 99.400 161.963
201803 138.090 99.200 158.135
201806 138.396 99.200 158.486
201809 141.744 99.900 161.182
201812 144.167 99.700 164.267
201903 150.190 99.700 171.129
201906 147.762 99.800 168.194
201909 148.984 100.100 169.077
201912 158.728 100.500 179.418
202003 148.029 100.300 167.658
202006 143.780 99.900 163.498
202009 153.196 99.900 174.205
202012 157.034 99.300 179.648
202103 169.391 99.900 192.621
202106 162.332 99.500 185.336
202109 159.241 100.100 180.717
202112 167.381 100.100 189.955
202203 175.918 101.100 197.668
202206 164.943 101.800 184.062
202209 166.851 103.100 183.844
202212 183.341 104.100 200.072
202303 209.903 104.400 228.400
202306 193.565 105.200 209.021
202309 203.044 106.200 217.192
202312 217.026 106.800 230.844
202403 217.081 107.200 230.041
202406 207.443 108.200 217.796
202409 201.253 108.900 209.939
202412 216.830 110.700 222.510
202503 220.853 111.100 225.823
202506 202.071 111.700 205.508
202509 206.831 112.000 209.786
202512 220.663 113.000 221.835
202603 246.247 112.700 248.213
202606 213.753 113.600 213.753

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円751.49 mean?
Santen Pharmaceutical Co (TSE:4536) has a Cyclically Adjusted Revenue per Share of 円751.49 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Santen Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円751.49. Overall, Santen Pharmaceutical Co has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円751.49 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円751.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (TSE:4536) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,722.07, compared to a current price of 円1,916.00 — trading 11.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円751.49. Santen Pharmaceutical Co's overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Santen Pharmaceutical Co (TSE:4536), the current Cyclically Adjusted Revenue per Share is 円751.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (TSE:4536) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of 円1,916.00 is trading 11.3% above its estimated GF Value™ of 円1,722.07. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TSE:4536:

  • Cyclically Adjusted Revenue per Share: 円751.49
  • GF Value™: 円1,722.07 vs. price of 円1,916.00 (11.3% above fair value)
  • GF Score™: 88/100

No single metric tells the full story. See the TSE:4536 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
88GF Score

Get the complete analysis for TSE:4536

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,916.00
Price
円1,722.07
GF Value